Skip Navigation



Journal of the National Cancer Institute Advance Access published online on November 5, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp403
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pritchard, K. I.
Right arrow Articles by Chia, S.
PubMed
Right arrow Articles by Pritchard, K. I.
Right arrow Articles by Chia, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved.

CORRESPONDENCE

Response

Kathleen I. Pritchard, Frances O'malley, Lois Shepherd, Mark N. Levine, Dongsheng Tu, Vivien Bramwell, Irene Andrulis, Stephen Chia

Affiliations of authors: Department of Pathobiology and Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada (FO, IA); Department of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada (SC); NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada (DT, LS); Department of Medical Oncology, McMaster University, Hamilton, ON, Canada (MNL); Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada (VB); Department of Medical Oncology, University of Calgary, Calgary, AB, Canada (VB); Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada (IA); Department of Laboratory medicine and Pathobiology (FPO, ILA), Sunnybrook Odette Cancer Centre, Toronto, ON, Canada (KYIP); Department of Medicine, University of Toronto, Toronto, ON, Canada (KYIP)

Correspondence to: Kathleen I. Pritchard, MD, FRCPC, Sunnybrook Odette Cancer Centre, 2075 Bayview Ave, T2-107, Toronto, ON, Canada M4N 3M5 (e-mail: kathy.pritchard@sunnybrook.ca).

The first 10% of the full text of this article appears below.

We are pleased to respond to the letter of Oakman, Moretti, Sotiriou, Viale, and Di Leo regarding our publication (1). We believe, as we stated in the conclusion of this article, that anthracycline benefit is associated with HER2 amplification and with TOP2A alterations. Certainly, our data and those of many others support the relationship between HER2 amplification or overexpression (2), TOP2A alterations (. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?